Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Pathogens ; 10(6)2021 May 29.
Article in English | MEDLINE | ID: mdl-34072394

ABSTRACT

Xylella fastidiosa subsp. pauca is the causal agent of "olive quick decline syndrome" in Salento (Apulia, Italy). On April 2015, we started interdisciplinary studies to provide a sustainable control strategy for this pathogen that threatens the multi-millennial olive agroecosystem of Salento. Confocal laser scanning microscopy and fluorescence quantification showed that a zinc-copper-citric acid biocomplex-Dentamet®-reached the olive xylem tissue either after the spraying of the canopy or injection into the trunk, demonstrating its effective systemicity. The biocomplex showed in vitro bactericidal activity towards all X. fastidiosa subspecies. A mid-term evaluation of the control strategy performed in some olive groves of Salento indicated that this biocomplex significantly reduced both the symptoms and X. f. subsp. pauca cell concentration within the leaves of the local cultivars Ogliarola salentina and Cellina di Nardò. The treated trees started again to yield. A 1H-NMR metabolomic approach revealed, upon the treatments, a consistent increase in malic acid and γ-aminobutyrate for Ogliarola salentina and Cellina di Nardò trees, respectively. A novel endotherapy technique allowed injection of Dentamet® at low pressure directly into the vascular system of the tree and is currently under study for the promotion of resprouting in severely attacked trees. There are currently more than 700 ha of olive groves in Salento where this strategy is being applied to control X. f. subsp. pauca. These results collectively demonstrate an efficient, simple, low-cost, and environmentally sustainable strategy to control this pathogen in Salento.

2.
AIDS ; 27(10): 1641-55, 2013 Jun 19.
Article in English | MEDLINE | ID: mdl-23449349

ABSTRACT

OBJECTIVE: To increase equitable access to life insurance for HIV-positive individuals by identifying subgroups with lower relative mortality. DESIGN: Collaborative analysis of cohort studies. METHODS: We estimated relative mortality from 6 months after starting antiretroviral therapy (ART), compared with the insured population in each country, among adult patients from European cohorts participating in the ART Cohort Collaboration (ART-CC) who were not infected via injection drug use, had not tested positive for hepatitis C, and started triple ART between 1996-2008. We used Poisson models for mortality, with the expected number of deaths according to age, sex and country specified as offset. RESULTS: There were 1236 deaths recorded among 34,680 patients followed for 174,906 person-years. Relative mortality was lower in patients with higher CD4 cell count and lower HIV-1 RNA 6 months after starting ART, without prior AIDS, who were older, and who started ART after 2000. Compared with insured HIV-negative lives, estimated relative mortality of patients aged 20-39 from France, Italy, United Kingdom, Spain and Switzerland, who started ART after 2000 had 6-month CD4 cell count at least 350 cells/µl and HIV-1 RNA less than 104 copies/ml and without prior AIDS was 459%. The proportion of exposure time with relative mortality below 300, 400, 500 and 600% was 28, 43, 61 and 64%, respectively, suggesting that more than 50% of patients (those with lower relative mortality) could be insurable. CONCLUSION: The continuing long-term effectiveness of ART implies that life insurance with sufficiently long duration to cover a mortgage is feasible for many HIV-positive people successfully treated with ART for more than 6 months.


Subject(s)
HIV Infections/mortality , Adolescent , Adult , Anti-HIV Agents/therapeutic use , Cohort Studies , Drug Therapy, Combination , Female , France/epidemiology , HIV Infections/drug therapy , Humans , Insurance, Health/statistics & numerical data , Italy/epidemiology , Life Tables , Male , Middle Aged , Risk Factors , Spain/epidemiology , Switzerland/epidemiology , United Kingdom/epidemiology , Young Adult
3.
J Cardiovasc Magn Reson ; 9(6): 891-8, 2007.
Article in English | MEDLINE | ID: mdl-18066749

ABSTRACT

Progressive left ventricular hypertrophy is the hallmark of cardiac manifestations in patients with Fabry disease. Cardiovascular magnetic resonance with tissue tagging allows detailed assessment of the cardiac motion pattern. The aim was to test the hypothesis that not only Fabry patients with severe left ventricular hypertrophy exhibit changes in myocardial motion, but also Fabry patients with normal left ventricular mass. Magnetic resonance tagging using slice following complementary spatial modulation of magnetization (CSPAMM) combined with harmonic phase analysis (HARP) was applied to measure left ventricular shortening and contraction. Additionally, left ventricular rotation and global left ventricular torsion were examined. Twenty-nine Fabry patients grouped in patients with (n = 13) and without (n = 16) left ventricular hypertrophy were compared with 29 age and sex matched healthy volunteers. Long axis shortening and circumferential contraction showed reduced peak values with increasing left ventricular mass and were significantly reduced in Fabry patients with left ventricular hypertrophy (p < 0.001 and p < 0.05, respectively). Torsional deformation and apical rotation were increased both in Fabry patients with left ventricular hypertrophy as well as in patients with normal left ventricular mass (p < 0.001 for torsion) compared with controls. Applying the magnetic resonance tagging acquisition and analysis methods, myocardial motion abnormalities could not only be measured in Fabry patients with left ventricular hypertrophy but also in patients without macroscopic cardiac involvement.


Subject(s)
Fabry Disease/physiopathology , Magnetic Resonance Imaging, Cine , Ventricular Dysfunction, Left/physiopathology , Adult , Analysis of Variance , Case-Control Studies , Female , Humans , Image Processing, Computer-Assisted , Linear Models , Male , Rotation , Torsion Abnormality/physiopathology
4.
AJR Am J Roentgenol ; 187(6): 1463-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17114538

ABSTRACT

OBJECTIVE: Segmental arterial mediolysis is a rare noninflammatory vascular disease of the abdominal splanchnic arteries. The purpose of our study was to retrospectively describe the CT angiography (CTA) findings of this disease and the evolution of those findings over time in five patients. CONCLUSION: Comparison of CTA and digital subtraction angiography suggests that CTA is useful to diagnose symptomatic segmental arterial mediolysis. Midterm CTA follow-up (median, 3 years) indicates that segmental arterial mediolysis lesions may resolve or remain unchanged.


Subject(s)
Angiography/methods , Splanchnic Circulation , Tomography, X-Ray Computed/methods , Vascular Diseases/diagnostic imaging , Aged , Angiography, Digital Subtraction , Female , Humans , Male , Middle Aged , Retrospective Studies
5.
Am J Hypertens ; 19(8): 782-7, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16876675

ABSTRACT

BACKGROUND: Fabry disease is a rare X-linked disease arising from deficiency of alpha-galactosidase A. It results in early death related to renal, cardiac, and cerebrovascular disease, which are also important outcomes in patients with elevated blood pressure (BP). The prevalence of uncontrolled hypertension, as well as the effect of enzyme replacement therapy on BP, in patients with Fabry disease is unknown. METHODS: We examined uncontrolled hypertension (systolic BP [SBP] >or=130 mm Hg or diastolic BP [DBP] >or=80 mm Hg) among 391 patients with Fabry disease who were participating in the Fabry Outcome Survey (FOS). RESULTS: Uncontrolled hypertension was present in 57% of men and 47% of women. In patients with chronic kidney disease (CKD) stage 1 (n100), median SBP was 120 mm Hg and median DBP was 74 mm Hg. In patients with CKD stage 2 (n172), median SBP was 125 mm Hg and median DBP was 75 mm Hg. In patients with CKD stage 3 (n63), median SBP was 130 mm Hg and median DBP was 75 mm Hg. There was a significant decrease in both SBP and DBP during a 2-year course of enzyme replacement therapy. CONCLUSIONS: This study revealed a high prevalence of uncontrolled hypertension among patients with Fabry disease. Thus there is a need to improve BP control and renoprotection in patients with Fabry disease.


Subject(s)
Fabry Disease/complications , Fabry Disease/epidemiology , Hypertension/complications , Hypertension/epidemiology , Antihypertensive Agents/therapeutic use , Blood Pressure , Dialysis , Fabry Disease/drug therapy , Fabry Disease/physiopathology , Female , Humans , Hypertension/drug therapy , Hypertension/physiopathology , Kidney/physiology , Kidney Transplantation , Male , Prevalence , Sex Ratio
7.
Acta Paediatr ; 95(1): 86-92, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16498740

ABSTRACT

BACKGROUND: Fabry disease is a rare X-linked disorder caused by deficient activity of the enzyme alpha-galactosidase A. This produces progressive lysosomal accumulation of globotriaosylceramide throughout the body, leading to organ failure and premature death. AIM: Here, we present the clinical manifestations of Fabry disease in children enrolled in FOS--the Fabry Outcome Survey--a European database of the natural history of Fabry disease and the effects of enzyme replacement therapy with agalsidase alfa (Replagal). METHODS: Currently, there are 545 patients in FOS, from 11 European countries. We analysed the baseline demographic and clinical characteristics of 82 of these patients (40 boys, 42 girls) who were below 18 y of age. The median age at evaluation (defined as the median age at entry into FOS) was 12.5 and 13.2 y for boys and girls, respectively. RESULTS: The most frequent early clinical manifestations of Fabry disease were neurological (acroparaesthesiae, altered temperature sensitivity) and gastrointestinal symptoms (altered bowel habits and abdominal pain), which were documented in about 80% and 60% of patients, respectively, at the time of evaluation and subsequent entry into FOS. Tinnitus, vertigo, fatigue and angiokeratoma were present in over 40% of patients. Symptoms were noted in early childhood and occurred with similar frequency in boys and girls, although the onset of symptoms was 2-5 y later in girls than in boys. There was an approximately 3-y delay from onset of symptoms to diagnosis, and patients were frequently misdiagnosed. CONCLUSION: Although the life-threatening complications of Fabry disease, such as stroke and renal and heart failure, are not seen in children, the present analysis shows that other symptoms are common and may have an impact on quality of life.


Subject(s)
Fabry Disease/physiopathology , Adolescent , Age of Onset , Child , Child, Preschool , DNA Mutational Analysis , Fabry Disease/diagnosis , Fabry Disease/drug therapy , Female , Heterozygote , Humans , Isoenzymes/therapeutic use , Male , Outcome Assessment, Health Care , Recombinant Proteins , alpha-Galactosidase/metabolism , alpha-Galactosidase/therapeutic use
8.
Kidney Int ; 67(5): 1955-60, 2005 May.
Article in English | MEDLINE | ID: mdl-15840043

ABSTRACT

BACKGROUND: The prevalence and causes of anemia among patients with Fabry disease are unknown. METHODS: In a cross-sectional study we examined hemoglobin concentrations of patients with Fabry disease using a large international database, the Fabry Outcome Survey (FOS), and analyzed the association of renal function, heart failure, gastrointestinal symptoms, and inflammation, with anemia (hemoglobin <12 g/dL in females and <13 g/dL in males). RESULTS: Anemia was present in 34% of 345 patients with Fabry disease. Median hemoglobin in 158 females was 12.9 g/dL and the median hemoglobin of 187 male patients was 13.2 g/dL. The prevalence of anemia among females was 20%, and among males 47%. Among patients with normal renal function [estimated glomerular filtration rate (GFR) >90 mL/min/1.73 m(2)] and anemia, heart failure [New York Heart Association (NYHA) class II to IV] and/or elevated C-reactive protein (CRP) levels were documented in 82% of patients. Up to 67% of patients with decreased estimated GFR presented with anemia. There was also a trend for lower hemoglobin levels among patients with signs of inflammation (defined by an elevated CRP level). We observed no association of the presence of gastrointestinal symptoms with anemia. Analyses in 53 patients receiving enzyme replacement therapy for up to 2 years, suggest no effect on anemia. CONCLUSION: The results of this study point to a high prevalence of anemia among patients with Fabry disease that is in most instances related to impaired renal function, heart failure, and inflammation. This finding may be of clinical relevance, because anemia is a major risk factor for patients with kidney disease, heart failure, or stroke, which are important manifestations of Fabry disease.


Subject(s)
Anemia/etiology , Fabry Disease/complications , Adult , Anemia/blood , C-Reactive Protein/metabolism , Cross-Sectional Studies , Data Collection , Databases, Factual , Europe , Fabry Disease/blood , Fabry Disease/drug therapy , Fabry Disease/physiopathology , Female , Gastrointestinal Diseases/blood , Gastrointestinal Diseases/etiology , Glomerular Filtration Rate , Heart Failure/blood , Heart Failure/etiology , Hemoglobins/analysis , Humans , Isoenzymes/therapeutic use , Male , Middle Aged , alpha-Galactosidase/therapeutic use
9.
Hum Mutat ; 25(4): 412, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15776423

ABSTRACT

Fabry disease (FD) is an X-chromosomal disorder caused by mutations in the GLA gene encoding the lysosomal enzyme alpha-galactosidase A. We performed mutation screening on a cohort of 121 patients including 84 male and 37 female index cases and identified a total of 90 different mutations, 34 of which are reported for the first time here. Both point mutations (74.4%) and 'short length' rearrangements (25.6%) were found, including missense (54.4%), nonsense (14.4%), and splice site point mutations (5.6%), deletions (17.8%) or insertions/duplications (5.6%) of a few nucleotides, and complex rearrangements including larger deletions (2.2%). GLA mutations were identified in 82 (97.6%) of the 84 unrelated male patients.


Subject(s)
Fabry Disease/genetics , alpha-Galactosidase/genetics , Adolescent , Adult , Amino Acid Sequence , Base Sequence , Cohort Studies , DNA Mutational Analysis , Female , Gene Deletion , Humans , Male , Middle Aged , Molecular Sequence Data , Point Mutation
10.
Lymphat Res Biol ; 1(3): 185-9, 2003.
Article in English | MEDLINE | ID: mdl-15624436

ABSTRACT

BACKGROUND: Lymphedema has been described in a few cases of Fabry disease. The etiology of lymphedema in Fabry disease is unknown. The aim of the study was to evaluate morphology and function of lymphatic microvessels in this disease. METHODS AND RESULTS: In five male patients with Fabry disease, the initial lymphatic microvessels of the skin were studied in vivo, using a nearly atraumatic technique of fluorescence microlymphography and measurement of lymph capillary pressure. In addition, five female patients heterozygous for Fabry disease and 12 healthy controls were studied. The maximum spread of the fluorescent macromolecular dye into the network of superficial skin lymphatics was increased in the three male patients presenting with lymphedema (25, 26, and 45 mm, respectively). In the two male patients without swollen legs, the maximum spread of the dye was 3 and 7 mm, respectively, and in the female patients 8.8 mm (range, 4-17 mm), whereas in the healthy controls it reached only 4.3 mm (range, 1-7 mm). Fragmentation of the microlymphatic network was found in all patients, but not in controls. In controls, the diameter of the microvessels varied in a very narrow range (45-75 microm); in patients, the range was 15-150 microm. In patients with lymphedema, microlymphatic hypertension was present. CONCLUSION: In patients with Fabry disease severe structural and functional changes of the initial lymphatics of the skin are present.


Subject(s)
Fabry Disease/diagnosis , Fabry Disease/genetics , Fabry Disease/pathology , Lymphatic Vessels/pathology , Lymphedema/pathology , Adolescent , Adult , Capillaries/pathology , Endothelium, Lymphatic/pathology , Female , Heterozygote , Humans , Lymph , Lymphography/methods , Male , Microcirculation , Microscopy, Fluorescence , Middle Aged , Pressure , Sex Factors , Skin/pathology
11.
Rev Med Suisse Romande ; 122(9): 449-53, 2002 Sep.
Article in French | MEDLINE | ID: mdl-12422475

ABSTRACT

Fabry disease is a X-linked sphingolipid storage disorder resulting from the defective activity of the lysosomal enzyme, alpha-galactosidase A. Hemizygotes develop severe multisystemic disease, dominated by renal failure and progressive neurological and cardiac involvement, causing premature death. Thirty percent of heterozygotes have severe involvement of one or several organs. With developments in molecular biology, it is now possible to produce the human recombinant enzyme alpha-galactosidase A. More than 20 patients are now treated in Switzerland.


Subject(s)
Fabry Disease/diagnosis , Biopsy , Chromosomes, Human, X/genetics , Fabry Disease/drug therapy , Fabry Disease/genetics , Galactosidases/blood , Galactosidases/therapeutic use , Humans , Male , Middle Aged , Pedigree , alpha-Galactosidase/blood , alpha-Galactosidase/therapeutic use
12.
Dermatology ; 204(3): 244-7, 2002.
Article in English | MEDLINE | ID: mdl-12037456

ABSTRACT

We report on a patient with Klippel-Trenaunay (KT) syndrome, a factor VII deficiency and a copper metabolism disorder. The KT syndrome involved the left leg and, histologically, the liver. Dermatological examination, duplex ultrasonography and a skin and liver biopsy verified the KT syndrome. A long prothrombin time prompted clotting studies revealing a factor VII deficiency while the other factors were in the normal range. Further laboratory examinations showed a copper metabolism disorder similar to Wilson's disease with a low serum ceruloplasmin level, elevated copper concentration in the urine and increased copper deposition in the liver. Neither liver cirrhosis nor a Kayser-Fleischer corneal ring was present. Sequencing analysis of the Wilson's disease gene ATB7B showed no mutations. The occurrence of these three uncommon pathologies in a single patient has not been described to date, which may suggest a mutation in a hypothetical common regulatory gene leading to this unusual phenotype.


Subject(s)
Copper/metabolism , Factor VII Deficiency/diagnosis , Klippel-Trenaunay-Weber Syndrome/pathology , Metabolism, Inborn Errors/diagnosis , Skin/pathology , Adult , Biopsy, Needle , Factor VII Deficiency/complications , Humans , Immunohistochemistry , Klippel-Trenaunay-Weber Syndrome/complications , Klippel-Trenaunay-Weber Syndrome/diagnosis , Male , Metabolism, Inborn Errors/complications , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...